Walgreens outlines results of medication adherence studies
DEERFIELD, Ill. — Walgreens unveiled the results of research, conducted by the drug store chain, that demonstrated how its approach to community pharmacy ultimately helped improve outcomes through cost savings, pharmacist-led face-to-face patient counseling and specialized services for disease management.
New research results, presented by Walgreens at the Academy of Managed Care Pharmacy’s 24th Annual Meeting and Expo last week in San Francisco, included:
Prescription Savings Club membership drives medication adherence: The study, which assessed the impact of enrollment in Walgreens Prescription Savings Club on patient adherence to prescriptions used to treat diabetes, found that PSC members were nearly 10% more adherent to diabetes medications, compared with non-PSC members (77.9% versus 68%);
Impact of community pharmacist-led counseling on patient medication adherence: The pharmacist-led counseling for patients that were newly prescribed statin and thyroid medications resulted in an increase in one-year patient medication possession from 44% before the introduction of the program to 56% after the introduction of the program. Medication possession in a control group of patients of similar pharmacies without the program showed no significant increase in medication possession; and
Impact of HIV-specialized pharmacies on adherence to antiretroviral therapy: Walgreens HIV Centers of Excellence pharmacies, which offer specialized services for HIV patients aimed at combatting barriers to adherence, found that 62% of patients at such pharmacies had adherence of 85% or more, compared with 57% of patients using community pharmacies.
"At Walgreens, our number one priority is offering our patients innovative, accessible and personalized solutions to staying well," said Kermit Crawford, Walgreens president of pharmacy, health and wellness services and solutions. "And providing a support system to facilitate consistent adherence with prescribed medications is a key component of this. This research highlights how three initiatives — our Prescription Savings Club program, our face-to-face pharmacist disease management counseling, and our specialty pharmacy offerings — can all meaningfully help improve adherence. These types of offerings not only benefit our patients, but also the overall healthcare system by ultimately helping improve outcomes and potentially reduce costs."
This investigate highlights how trine initiatives - our Medicine Fund Society system, our face-to-face chemist disease management counseling, and our specialty pharmacy offerings
One might ask how improved medication possession translates to adherence or improved outcomes. Is possession intended to be a proxy for adherence? If so, it's a questionale relationship. Overall, I do think these type of interventions work, but the data needs to flow from solid methodology. I'm not sure how solid this methodology really is.
BioScrip appoints new CFO
ELMSFORD, N.Y. — Specialty pharmacy provider BioScrip has appointed Hai Tran as SVP, treasurer and CFO, the company said.
Effective May 14, Tran will replace M.J. Graves, who has served as the company’s interim CFO and treasurer since January 2011.
"Hai has a successful and long-standing track record, which combines strong financial skills, depth of experience in managing financial and accounting operations in high-growth environments and acquiring and integrating businesses," BioScrip president and CEO Rick Smith said. "We believe Hai’s experience will be particularly important as we execute the next phase of our growth initiatives, specifically expanding our footprint in infusion services and continuing to execute in our other businesses where we have key strengths."
Tran previously served as CFO and VP international of Harris Healthcare Solutions, a division of Harris. Prior to that, he served as CFO of the PBM Catalyst Health Solutions. He has also worked for Hanger Orthopedic Group, Cadmus Communications and other companies.
No comments found
Dr. Reddy’s launches generic version of Zyprexa
HYDERABAD, India — Dr. Reddy’s Labs has launched a generic version of an Eli Lilly drug used to treat psychiatric disorders, the company said Tuesday.
Dr. Reddy’s announced the launch of olanzapine tablets in the 2.5-mg, 5-mg, 7.5-mg, 10-mg and 15-mg strengths.
The drug is a generic version of Zyprexa, used to treat schizophrenia and bipolar disorder. Generic and branded versions of the drug had sales of about $3.28 billion during the 12-month period ended in January, according to IMS Health.
No comments found